GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.16
−4.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.5M | 3.5M | 5.8M | 6.5M | 8.8M |
| SG&A Expense | 12.8M | 8.9M | 8.6M | 7.1M | 12.4M |
| General & Admin Expense | 6.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 46.0K | — | — | — | — |
| Total Operating Expenses | 16.3M | 12.4M | 14.4M | 13.6M | 21.3M |
| Cost and Expenses | 16.3M | 12.4M | 14.4M | 13.6M | 21.3M |
| Operating Income (EBIT) | (16.3M) | (12.4M) | (14.4M) | (13.6M) | (21.3M) |
| Non-Operating | |||||
| Interest Income | 178.0K | 123.0K | 402.0K | 780.0K | 292.0K |
| Interest Expense | 127.0K | 127.0K | — | 213.0K | 8.0K |
| Net Interest Income | 51.0K | (4.0K) | 402.0K | 567.0K | 284.0K |
| Other Non-Op Income/Expense | (5.7M) | (15.9M) | 1.2M | 6.0M | 373.0K |
| Non-Operating Income (excl Interest) | 4.0M | 15.8M | (1.2M) | (6.0M) | (381.0K) |
| EBT (Pre-Tax Income) | (22.1M) | (28.4M) | (13.2M) | (7.6M) | (20.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (22.1M) | (28.4M) | (13.2M) | (7.6M) | (20.9M) |
| Earnings from Cont. Ops | (22.1M) | (28.4M) | (13.2M) | (7.6M) | (20.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.8M) | (34.4M) | (13.2M) | (7.6M) | (20.9M) |
| Per Share | |||||
| Basic EPS | ($104.00) | ($156.25) | ($173.50) | ($141.00) | ($16.50) |
| Diluted EPS | ($104.00) | ($156.25) | ($173.50) | ($141.00) | ($16.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.6M | 220530 | 75880 | 53880 | 1.3M |
| Diluted Shares Outstanding | 1.6M | 220530 | 75880 | 53920 | 1.3M |
| Profitability Metrics | |||||
| EBITDA | (20.3M) | (28.2M) | (13.2M) | 6.0M | (21.0M) |
| D&A | — | — | — | 13.6M | — |
| EBIT | (20.3M) | (28.2M) | (13.2M) | (7.6M) | (20.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026